JP2023519099A5 - - Google Patents

Info

Publication number
JP2023519099A5
JP2023519099A5 JP2022548588A JP2022548588A JP2023519099A5 JP 2023519099 A5 JP2023519099 A5 JP 2023519099A5 JP 2022548588 A JP2022548588 A JP 2022548588A JP 2022548588 A JP2022548588 A JP 2022548588A JP 2023519099 A5 JP2023519099 A5 JP 2023519099A5
Authority
JP
Japan
Application number
JP2022548588A
Other languages
Japanese (ja)
Other versions
JPWO2021163389A5 (https=
JP2023519099A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/017737 external-priority patent/WO2021163389A1/en
Publication of JP2023519099A publication Critical patent/JP2023519099A/ja
Publication of JPWO2021163389A5 publication Critical patent/JPWO2021163389A5/ja
Publication of JP2023519099A5 publication Critical patent/JP2023519099A5/ja
Pending legal-status Critical Current

Links

JP2022548588A 2020-02-12 2021-02-11 Bcma指向性キメラ抗原受容体t細胞組成物ならびにその方法および使用 Pending JP2023519099A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062975731P 2020-02-12 2020-02-12
US62/975,731 2020-02-12
PCT/US2021/017737 WO2021163389A1 (en) 2020-02-12 2021-02-11 Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof

Publications (3)

Publication Number Publication Date
JP2023519099A JP2023519099A (ja) 2023-05-10
JPWO2021163389A5 JPWO2021163389A5 (https=) 2024-02-21
JP2023519099A5 true JP2023519099A5 (https=) 2024-02-21

Family

ID=74860462

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548588A Pending JP2023519099A (ja) 2020-02-12 2021-02-11 Bcma指向性キメラ抗原受容体t細胞組成物ならびにその方法および使用

Country Status (11)

Country Link
US (1) US20230087953A1 (https=)
EP (1) EP4103203A1 (https=)
JP (1) JP2023519099A (https=)
KR (1) KR20220152227A (https=)
CN (1) CN115361955A (https=)
AU (1) AU2021219764A1 (https=)
BR (1) BR112022015968A2 (https=)
CA (1) CA3170153A1 (https=)
IL (1) IL295381B1 (https=)
MX (1) MX2022009830A (https=)
WO (1) WO2021163389A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
JP7447006B2 (ja) * 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド B細胞成熟抗原(bcma)に特異的なキメラ抗原受容体
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
KR20210113169A (ko) * 2018-11-01 2021-09-15 주노 쎄러퓨티크스 인코퍼레이티드 Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
WO2023196215A1 (en) * 2022-04-05 2023-10-12 Xcell Biosciences, Inc. Cell populations adapted to a tumor microenvironment
WO2024036167A2 (en) * 2022-08-09 2024-02-15 The Trustees Of The University Of Pennyslvania Methods for enhancing the anti-tumor activity of car t cells by co-expression of ch25h
KR20260005874A (ko) * 2023-02-28 2026-01-12 주노 쎄러퓨티크스 인코퍼레이티드 전신 자가면역 질환을 치료하기 위한 세포 요법
WO2025080994A1 (en) * 2023-10-13 2025-04-17 The General Hospital Corporation Chimeric antigen receptor (car)-t cell engaging antibody molecule (team) formulations and pharmaceutical compositions
WO2025098446A1 (zh) * 2023-11-07 2025-05-15 赛斯尔擎生物技术(上海)有限公司 抗bcma单域抗体及其应用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
FR2540122B1 (fr) 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
WO1986002077A1 (en) 1984-10-02 1986-04-10 Meade Harry M Production of streptavidin-like polypeptides
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
EP0700430B1 (en) 1993-06-04 2005-04-20 The United States of America as Represented by the Secretary of the Navy Methods for selectively stimulating proliferation of t cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
CA2211951A1 (en) 1995-02-09 1996-08-15 University Of Washington Modified-affinity streptavidin
WO1997011183A1 (en) 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
US5801115A (en) 1995-09-05 1998-09-01 Kataleuna Gmbh Catalyst composition and methods for using and preparing same
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
ATE186235T1 (de) 1996-04-24 1999-11-15 Claude Fell Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
AU6701498A (en) 1997-03-14 1998-09-29 Trustees Of Boston University Multiflavor streptavidin
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
HK1041454B (en) 1998-12-24 2004-12-31 生物安全股份有限公司 Blood separation system particularly for concentrating hematopoietic stem cells
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
MX2007011218A (es) 2005-03-23 2007-10-17 Biosafe Sa Sistema integrado para colectar, procesar y transplantar subconjuntos de celulas, incluyendo celulas madre adultas para medicina regenerativa.
CA2682527C (en) 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP2406284B9 (en) 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
TR201811128T4 (tr) 2011-07-18 2018-08-27 Iba Gmbh Bir hedef hücrenin tersinir şekilde boyama yöntemi.
KR102134932B1 (ko) 2011-11-11 2020-07-17 프레드 헛친슨 켄서 리서치 센터 암을 위한 사이클린 a1―표적화된 t―세포 면역요법
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
RU2746407C1 (ru) 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Хроматографическое выделение клеток и других сложных биологических материалов
SG10201609210SA (en) 2012-05-03 2016-12-29 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US9599590B2 (en) 2012-10-12 2017-03-21 Sage Science, Inc. Side-eluting molecular fractionator
WO2014076277A1 (en) 2012-11-16 2014-05-22 Iba Gmbh Streptavidin muteins and methods of using them
DE112012007250B4 (de) 2012-12-20 2024-10-24 Mitsubishi Electric Corp. Fahrzeuginterne Vorrichtung und Programm
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
BR112016024072B1 (pt) 2014-04-16 2021-02-09 Juno Therapeutics Gmbh método in vitro de estimular uma população de células
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
WO2016061416A1 (en) 2014-10-15 2016-04-21 Sage Science, Inc. Apparatuses, methods and systems for automated processing of nucleic acids and electrophoretic sample preparation
CN107109438B (zh) 2014-11-05 2021-09-03 朱诺治疗学股份有限公司 用于转导及细胞处理的方法
KR20240135036A (ko) 2014-12-05 2024-09-10 메모리얼 슬로안 케터링 캔서 센터 B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
AU2015357526B2 (en) 2014-12-05 2022-03-17 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
EA036379B1 (ru) * 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
US11248238B2 (en) 2015-10-22 2022-02-15 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
SG11201908271WA (en) 2017-03-14 2019-10-30 Juno Therapeutics Inc Methods for cryogenic storage
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
US20200078404A1 (en) * 2017-05-01 2020-03-12 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
CN111263641B (zh) * 2017-08-09 2025-10-31 朱诺治疗学股份有限公司 用于制备基因工程化细胞的方法和组合物
AU2018313950A1 (en) * 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
JP7447006B2 (ja) * 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド B細胞成熟抗原(bcma)に特異的なキメラ抗原受容体
SG11202003427XA (en) * 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
CA3084446A1 (en) * 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
WO2019113557A1 (en) * 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
CA3105813A1 (en) * 2018-07-11 2020-01-16 Celgene Corporation Uses of anti-bcma chimeric antigen receptors

Similar Documents

Publication Publication Date Title
CN305552947S (https=)
CN305554193S (https=)
CN305557002S (https=)
CN305557530S (https=)
CN305560189S (https=)
CN305561119S (https=)
CN305562429S (https=)
CN305614408S (https=)
CN305637272S (https=)
CN305640057S (https=)
CN305658856S (https=)
CN305659789S (https=)
CN305664214S (https=)
CN305665117S (https=)
CN305670310S (https=)
CN305694124S (https=)
CN305694421S (https=)
CN305696699S (https=)
CN305698199S (https=)
CN305701458S (https=)
CN305732495S (https=)
CN305732823S (https=)
CN305782144S (https=)
CN305782414S (https=)
CN305950284S (https=)